716 related articles for article (PubMed ID: 15756005)
1. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
[TBL] [Abstract][Full Text] [Related]
2. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
3. AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples.
Shih LY; Liang DC; Huang CF; Wu JH; Lin TL; Wang PN; Dunn P; Kuo MC; Tang TC
Leukemia; 2006 Apr; 20(4):604-9. PubMed ID: 16453003
[TBL] [Abstract][Full Text] [Related]
4. CEBPalpha mutations in childhood acute myeloid leukemia.
Liang DC; Shih LY; Huang CF; Hung IJ; Yang CP; Liu HC; Jaing TH; Wang LY; Chang WH
Leukemia; 2005 Mar; 19(3):410-4. PubMed ID: 15618961
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.
Lorenzo F; Nishii K; Monma F; Kuwagata S; Usui E; Shiku H
Leuk Res; 2006 Oct; 30(10):1235-9. PubMed ID: 16533529
[TBL] [Abstract][Full Text] [Related]
7. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
8. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance.
Georgiou G; Karali V; Zouvelou C; Kyriakou E; Dimou M; Chrisochoou S; Greka P; Dufexis D; Vervesou E; Dimitriadou E; Efthymiou A; Petrikkos L; Dima K; Lilakos K; Panayiotidis P
Br J Haematol; 2006 Aug; 134(3):302-6. PubMed ID: 16787503
[TBL] [Abstract][Full Text] [Related]
9. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
Wang J; Wang T; Li S; Lin L; Gang Y
Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
[TBL] [Abstract][Full Text] [Related]
10. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML.
Kaeferstein A; Krug U; Tiesmeier J; Aivado M; Faulhaber M; Stadler M; Krauter J; Germing U; Hofmann WK; Koeffler HP; Ganser A; Verbeek W
Leukemia; 2003 Feb; 17(2):343-9. PubMed ID: 12592334
[TBL] [Abstract][Full Text] [Related]
11. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
[TBL] [Abstract][Full Text] [Related]
13. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
[TBL] [Abstract][Full Text] [Related]
14. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
Kuo MC; Liang DC; Huang CF; Shih YS; Wu JH; Lin TL; Shih LY
Leukemia; 2009 Aug; 23(8):1426-31. PubMed ID: 19282830
[TBL] [Abstract][Full Text] [Related]
15. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
Wulfert M; Küpper AC; Tapprich C; Bottomley SS; Bowen D; Germing U; Haas R; Gattermann N
Exp Hematol; 2008 May; 36(5):577-86. PubMed ID: 18439489
[TBL] [Abstract][Full Text] [Related]
16. Analysis of immunohistochemical results of the ras oncogene product p21 in myelodysplastic syndromes.
Kalmantis T; Kalmanti M; Vassilaki M; Spandidos DA
Anticancer Res; 1993; 13(4):1103-6. PubMed ID: 8352532
[TBL] [Abstract][Full Text] [Related]
17. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
18. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders.
Caudill JS; Sternberg AJ; Li CY; Tefferi A; Lasho TL; Steensma DP
Br J Haematol; 2006 Jun; 133(6):638-41. PubMed ID: 16704439
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
20. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
Wang LH; Wang M; Zhou CL; Chen S; Zhang XW; Xing HY; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]